Bronchopulmonary Dysplasia Clinical Trial
Official title:
Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease
Bronchopulmonary dysplasia (BPD), also known as chronic lung disease (CLD), is a major complication of premature birth and is associated with a significant increased risk of complications including death. Diuretics have been used for decades in babies with BPD and are considered a standard of care. Patients receive electrolyte supplementation to replace the electrolytes removed by the diuretics. Spironolactone is not as good as other diuretics at removing extra fluid, but it is different from chlorothiazide and furosemide because instead of removing potassium, it actually can increase potassium levels in our body. Spironolactone is used with chlorothiazide to try to minimize the potassium lost; therefore, reduce the electrolyte supplementation needed. However, studies have suggested that preterm babies aren´t developed enough to appropriately respond to spironolactone. Also, one study has shown that adding spironolactone to chlorothiazide in patients with BPD has no effect on whether or not patients receive electrolyte supplementation. This study will examine whether there is a difference in the amount of electrolyte supplementation between patients receiving chlorothiazide only or chlorothiazide plus spironolactone. the investigators hypothesize there will be no difference in the amount of electrolyte supplementation between the two groups.
Bronchopulmonary dysplasia (BPD), also known as chronic lung disease (CLD), is a major
complication of premature birth and is associated with significant morbidity and mortality.
Bronchopulmonary dysplasia most commonly affects preterm infants who have required prolonged
aggressive mechanical ventilation and/or oxygen supplementation. Risk factors associated
with BPD include degree of prematurity, infection, mechanical ventilation, oxygen
concentration, and nutritional status. Despite significant advances in the care of preterm
infants and improved survival, the incidence of BPD has been fairly static over the past
decade.
Diuretics and fluid restriction are considered a mainstay of therapy in the management of
BPD to combat interstitial alveolar edema. Short courses of furosemide followed by long-term
therapy using a thiazide diuretic with concurrent spironolactone have shown improvement in
pulmonary function and better outcomes. Double-blinded, randomized, placebo-controlled
trials have shown improvement in pulmonary compliance, airway resistance, infants alive at
discharge, and a decrease in fraction of inspired oxygen and need for furosemide boluses.
Spironolactone is a competitive aldosterone receptor antagonist that acts on the distal
convoluted tubule and collecting duct to facilitate sodium excretion while conserving
potassium and hydrogen ions. Since only a minimal amount of sodium filtered by the
glomerulus reaches the distal tubule, spironolactone is considered a weak diuretic.
Spironolactone is primarily used with chlorothiazide for its potassium-sparing effect to
reduce the need for electrolyte supplementation. There has only been one prospective,
randomized, double-blind, placebo-controlled study comparing chlorothiazide with or without
the addition of spironolactone in premature infants with chronic lung disease. This study
demonstrated no difference between the groups in the need for electrolyte supplementation,
electrolyte balance, or pulmonary function. In addition, preterm infants' distal tubules may
respond inadequately to aldosterone; thereby, limiting the role of spironolactone in this
patient population.
In the neonatal population, spironolactone is primarily used in addition with chlorothiazide
for its potassium-sparing effects to reduce the need for electrolyte supplementation.
However, evidence and current practice suggests the majority of patients still receive
electrolyte supplementation. One study evaluated spironolactone's effect on the need for
electrolyte supplementation, but there is no published data with a primary outcome
evaluating spironolactone's effect on the quantity of electrolyte supplementation. We
hypothesize there will be no difference in the amount of electrolyte supplementation between
the two groups.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04506619 -
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
|
||
Completed |
NCT04936477 -
Ventilation-perfusion (V/Q) Ratio and Alveolar Surface Area in Preterm Infants
|
N/A | |
Recruiting |
NCT05285345 -
Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Terminated |
NCT02524249 -
Early Versus Late Caffeine for ELBW Newborns
|
N/A | |
Completed |
NCT02249143 -
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
|
N/A | |
Active, not recruiting |
NCT01632475 -
Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
|
||
Completed |
NCT01460576 -
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
|
N/A | |
Completed |
NCT00419588 -
Growth of Airways and Lung Tissues in Premature and Healthy Infants
|
||
Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00319956 -
Trial II of Lung Protection With Azithromycin in the Preterm Infant
|
Phase 2 | |
Completed |
NCT00208039 -
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
|
N/A | |
Completed |
NCT00006401 -
Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
|
Phase 3 | |
Terminated |
NCT05030012 -
Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants
|
N/A | |
Completed |
NCT00006058 -
Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns
|
N/A | |
Completed |
NCT00005376 -
Premature Birth and Its Sequelae in Women
|
N/A | |
Completed |
NCT00011362 -
Dexamethasone Therapy in VLBW Infants at Risk of CLD
|
Phase 3 | |
Completed |
NCT00004805 -
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
|
N/A | |
Completed |
NCT05152316 -
The Baby Lung Study
|
||
Recruiting |
NCT04821453 -
NAVA vs. CMV Crossover in Severe BPD
|
N/A |